Clinical trials: Hypersensitivity
Diabetes Mellitus, Hypertension
Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up
The purpose of this study is to identify risk factors for insulin resistance and to investigate the influence of insulin sensitivity on development of cardiovascular risk markers like blood pressure, heart rate, body build…
- Conditions
- Diabetes Mellitus, Hypertension, Ischemic Heart Disease, Stroke
- Trial name
- INFO (NCT01412554)
- Where
- Norway
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Allergic Reaction, Wound Complication
Prineo Sensitivity Dressing Study
Wound complications can be devastating following total joint arthroplasty, resulting in an increased practice burden in the form of more frequent follow ups, increased clinic visits potential for wound dehiscence, superficial…
- Trial name
- NCT06011603
- Testing
- Prineo dressing
- Where
- United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Impaired Glucose Tolerance
Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Prediabetes (PD) was defined as an state in which glucose levels are above normal but not enough to meet criteria for the diagnosis of type 2 diabetes (T2D).
- Trial name
- NCT02708966
- Testing
- Gymnema Sylvestre
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Asthma, Allergic Rhinitis
Nasal Allergen Challenge in Rhinitic Subjects
Background: Nasal allergen challenge (NAC) is useful to study the pathophysiology of rhinitis, and multiple challenges may more adequately approximate natural exposure.
- Trial name
- NCT01286129
- Testing
- Nasal allergen challenge
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Laval University
Asthma
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
The primary objective of this trial is to evaluate the efficacy and safety of tiotropium 1.25 mcg (2 actuations of 0.625 mcg), tiotropium 2.5 mcg (2 actuations of 1.25 mcg) and tiotropium 5 mcg (2 actuations of 2.5 mcg) once…
- Trial name
- NCT01122680
- Testing
- Tiotropium bromide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD).
- Trial name
- NCT03585296
- Testing
- ATI-502
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aclaris Therapeutics, Inc.
Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant
Shortening Treatment by Advancing Novel Drugs
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of moxifloxacin, PA-824, and pyrazinamide treatments with varying doses and treatment lengths from 4 to 6 months in subjects with…
- Trial name
- STAND (NCT02342886)
- Testing
- Moxifloxacin, PA-824, Pyrazinamide
- Where
- 26 sites in Georgia, Kenya and 6 more
- Volunteers
- 284 people
- Sponsor
- Global Alliance for TB Drug Development
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Chronic Idiopathic Urticaria
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment…
- Trial name
- NCT01292473
- Testing
- Omalizumab
- Where
- 61 sites in United States, Denmark and 6 more
- Volunteers
- 323 people
- Sponsor
- Genentech, Inc.
Type 1 Diabetes Mellitus
Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
This protocol will investigate physiological parameters including insulin sensitivity and counterregulatory function using a mixed meal test and induced hypoglycemia in subjects with type I diabetes.
- Trial name
- BPK005 (NCT01439672)
- Testing
- Mixed meal and insulin challenge
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Virginia
Hormone-sensitive Metastatic Breast Cancer
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human beings show that this drug can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers.
- Trial name
- NCT01205685
- Testing
- OSI-906, Erlotinib, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01470118
- Testing
- alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Hereditary Angioedema
A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
The goal of this clinical trial is to test the drug navenibart in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of navenibart, and 2 other groups will get 2 doses of navenibart.
- Trial name
- NCT05695248
- Testing
- Navenibart
- Where
- 20 sites in United States, Bulgaria and 4 more
- Volunteers
- 29 people
- Sponsor
- Astria Therapeutics, Inc.
Asthma, Environmental Exposure
Home Air Quality Impact for Adults With Asthma
The purposes of this study are to determine the practicality of using home indoor air quality monitoring and a smartphone app to identify home air quality changes and how these changes affect adults with asthma.
- Conditions
- Asthma, Environmental Exposure, Home Environment Related Disease
- Trial name
- NCT05224076
- Testing
- Home Air Quality
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Kansas Medical Center
Asthma
Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants
This study has a randomized multiple-dose, placebo-controlled, parallel group design consisting of a 2-week open placebo Run-in Period followed by a 6-week Treatment Period with placebo, test product (budesonide 80 microgram…
- Trial name
- NCT02495168
- Testing
- Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)
- Where
- 17 sites in United States
- Volunteers
- 1,714 people
- Sponsor
- Actavis Inc.
Asthma
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic…
- Trial name
- DEAR (NCT02937168)
- Testing
- Reslizumab, Fludeoxyglucose F 18 (FDG)
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Atopic Conjunctivitis
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye).
- Trial name
- NCT00884585
- Testing
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Allergan
Healthy Volunteers
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult…
- Trial name
- NCT05405985
- Testing
- Nemolizumab
- Where
- 2 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Allergy, Peanut
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection…
- Trial name
- NCT04984876
- Testing
- ligelizumab
- Where
- 55 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.